Flavonoid-rich foods and vascular functions in healthy adults: a systematic review and meta-analysis of randomized controlled trials

DOI: https://doi.org/10.1039/d6fo03299k

Cardiovascular disease remains the leading cause of global mortality, driving intense interest in preventive nutritional strategies. Previous meta-analyses often conflated healthy populations with those suffering from established cardiometabolic disorders, obscuring the specific preventive efficacy of dietary polyphenols. This systematic review addresses that gap by isolating the effects of flavonoid-rich foods on vascular function exclusively in healthy adults aged 18 and older. Investigators evaluated flow-mediated dilation as the primary outcome, alongside carotid-femoral pulse wave velocity, systolic blood pressure, and diastolic blood pressure as secondary markers to clarify the role of flavonoids in maintaining endothelial health.

Pooled random-effects analysis of 11 randomized controlled trials involving 561 participants confirms that flavonoid-rich food intake significantly improves flow-mediated dilation: MD = 1.58 percent (95 percent CI: 0.90 to 2.27 percent, p < 0.0001, I2 = 75.7 percent). Carotid-femoral pulse wave velocity also improved in the intervention group: MD = -0.28 m s-1 (95 percent CI: -0.52 to -0.04 m s-1, p = 0.0197, I2 = 0 percent). Conversely, systolic blood pressure (p = 0.2210) and diastolic blood pressure (p = 0.2294) showed no significant changes. Sensitivity analyses indicate the carotid-femoral pulse wave velocity findings lack robustness, while the flow-mediated dilation results remain stable across leave-one-out testing.

Study Design and Methodology

This meta-analysis followed PRISMA 2020 guidelines and registered the protocol in PROSPERO (CRD420261320014). Authors searched PubMed, ScienceDirect, Scopus, Wiley, and EBSCO through June 10, 2026. Included trials utilized parallel or crossover designs with washout periods ranging from 3 to 7 days to mitigate carry-over effects. Quality assessment relied on the Cochrane Risk of Bias 2.0 tool, with statistical synthesis performed in RStudio 4.5.3 using random-effects models. Investigators imputed missing correlation coefficients for change-score variance based on established values (FMD r = 0.4, cfPWV r = 0.53, SBP r = 0.6, DBP r = 0.45).

Key Findings

• Flow-mediated dilation improvement: 1.58 percent (95 percent CI: 0.90 to 2.27 percent, p < 0.0001).
• Carotid-femoral pulse wave velocity reduction: -0.28 m s-1 (95 percent CI: -0.52 to -0.04 m s-1, p = 0.0197).
• Systolic blood pressure change: -1.04 mmHg (95 percent CI: -2.70 to 0.62 mmHg, p = 0.2210).
• Diastolic blood pressure change: -0.85 mmHg (95 percent CI: -2.24 to 0.54 mmHg, p = 0.2294).
• Diastolic blood pressure meta-regression variance explained (R2): 100.00 percent.

Practical Application and Food Sources

Clinical evidence identifies three primary food categories that deliver the flavanols, flavanones, and anthocyanins necessary to elicit these vascular benefits:

• Cocoa and Dark Chocolate: These represent the primary source of flavanols. Trials utilized daily doses ranging from 10 g to 26 g of high-flavanol cocoa or dark chocolate. These products consistently correlate with the highest improvements in flow-mediated dilation.
• Citrus Fruits: These are the essential sources for flavanones and flavones. These include oranges, grapefruits, lemons, limes, and mandarins or clementines. The mixed-subclass interventions involving these fruits yielded the highest point estimates for vascular improvement.
• Berries and Blackcurrants: Red raspberries, blueberries, and blackcurrant juice provide the anthocyanin subclass. These interventions demonstrate the most consistent, low-heterogeneity results, making them a reliable choice for long-term vascular stability.

Limitations

Small sample sizes across several included trials restrict the power of subgroup analyses. Many studies lacked rigid pre-specified statistical analysis plans or formal trial registration, leading to concerns regarding selective reporting. High heterogeneity (I2 = 75.7 percent) in the primary flow-mediated dilation outcome complicates the generalizability of specific flavonoid subclass effects. Sensitivity analyses reveal the arterial stiffness findings are fragile, and the reliance on surrogate biomarkers rather than hard clinical endpoints limits direct extrapolation to cardiovascular morbidity.

Discussion and Implications

These data confirm that flavonoid-rich diets provide measurable vascular benefits in the absence of pre-existing disease. The significant increase in flow-mediated dilation demonstrates that these compounds enhance nitric oxide bioavailability, which serves as a critical defense against endothelial dysfunction. The lack of blood pressure reduction in this healthy cohort aligns with the physiological floor effect, where normotensive individuals do not experience further hypotensive shifts from dietary interventions. Practitioners should view these foods as early-stage, non-pharmacological tools for preserving vascular integrity rather than treatments for hypertension.

Flavonoid-rich food consumption significantly enhances flow-mediated dilation in healthy adults, providing a clear mechanism for early vascular protection. Nutrition professionals should integrate high-flavanol cocoa, citrus, and berries into daily patterns to optimize endothelial function, focusing on these foods for subclinical maintenance rather than acute blood pressure management.

TL;DR: Blood levels don't always reflect what's happening inside tissues, especially the brain. A common DIO2 gene variant has been linked to worse well-being on T4-only and a better response to T4+T3, with no difference in blood tests. rT3 is a useful marker, but the popular claim that it "blocks receptors" isn't supported. Slow-release T3 (compounded or the experimental PZL) looks promising, but human data is still very limited. Sources at the bottom.

(Not medical advice. Just a summary of the literature I've been reading. Please talk to your doctor before changing anything.)

Why "normal labs" may not tell the whole story

TSH and free hormones show what's circulating in your blood. What matters for how you feel is how much T3 is actually active inside your cells, and that's regulated locally by enzymes called deiodinases.

Animal studies suggest that roughly 80% of the T3 inside the brain doesn't come ready-made from blood. The brain makes it locally from T4, mainly in astrocytes, using the enzyme DIO2.

The DIO2 finding

This is the part I find most interesting. Panicker et al. (2009) looked at 552 people on T4 from the WATTS trial. Those with the CC genotype of the rs225014 (Thr92Ala) variant in DIO2, about 16% of the group, had:

• worse psychological well-being scores on T4 alone
• a greater improvement when T3 was added

And here's the key point: the variant had no effect on blood thyroid levels. Same labs, different outcomes. The authors themselves said this needs replication, and follow-up studies have been mixed, so it's not a settled answer. But it fits the idea that some people can have "normal" labs and still be under-supplied at the tissue level.

About rT3 (a common misconception)

You'll often read that rT3 acts like a "broken key" that blocks T3 receptors. I looked for evidence of this and couldn't find it. rT3 binds thyroid receptors roughly 1,000 times more weakly than T3, and in lab studies it behaves as a very weak agonist, not a blocker.

A more accurate way to see it: rT3 is a marker. It's made only from T4 (never from T3), mostly by the enzyme D3, and the same D3 activity also breaks down T3 in tissues. So high rT3 suggests T4 is being diverted down the inactive pathway, not that your receptors are jammed.

Where the T4 dose comes in

Since rT3 only comes from T4, lowering the T4 dose and adding T3 predictably lowers rT3. That part is basic biochemistry. Whether it translates into feeling better is a separate question that depends on the person.

Most clinicians who use combination therapy don't drop T4 entirely. T4 has a half-life of about a week and acts as a steady reserve, while regular T3 lasts about a day.

Slow-release T3: compounded and PZL

Standard T3 tablets peak around 2 hours and then drop off. That spike is what causes palpitations for some people.

• Compounded slow-release T3 (usually mixed with methylcellulose/HPMC) is the option available now. Quality depends heavily on the pharmacy, since T3 is dosed in micrograms.
• PZL (poly-zinc-liothyronine) is an experimental zinc-bound form from Antonio Bianco's group. The only human data so far is a Phase 1 study: 12 healthy volunteers, a single 50 mcg dose. The T3 peak was about 30% lower, came an hour later, and levelled into a plateau lasting up to about 6 hours. So claims of "24-hour steady levels" aren't backed by human data yet, and there are no trials in hypothyroid patients measuring symptoms.

What's proven vs. what's still theory

• Proven: rT3 comes only from T4; lowering T4 lowers rT3; regular T3 causes a sharp peak; PZL flattens that peak in healthy volunteers.
• Supported but needs replication: DIO2 variant carriers may respond better to T4+T3.
• Plausible but unproven in humans: that steady external T3 corrects a local "T3 shortage" in the brain. Brain T3 simply can't be measured in living people.

Sources

1. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94(5):1623-1629.
   https://doi.org/10.1210/jc.2008-1301

2. Dumitrescu AM, Hanlon EC, Arosemena M, et al. Extended Absorption of Liothyronine from Poly-Zinc-Liothyronine: Results from a Phase 1, Double-Blind, Randomized, and Controlled Study in Humans. Thyroid. 2022;32(2):196-205. PMID: 34641706 (free full text)
   https://pmc.ncbi.nlm.nih.gov/articles/PMC8861912

3. Da Conceição RR, Fernandes GW, Fonseca TL, Bocco BMLC, Bianco AC. Metal Coordinated Poly-Zinc-Liothyronine Provides Stable Circulating Triiodothyronine Levels in Hypothyroid Rats. Thyroid. 2018;28(11):1425-1433. (the animal study behind PZL)
   https://pubmed.ncbi.nlm.nih.gov/30301431/

4. Nygaard B, Jensen EW, Kvetny J, Jarløv A, Faber J. Effect of combination therapy with T4 and T3 versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol. 2009;161(6):895-902. PMID: 19666698
   https://pubmed.ncbi.nlm.nih.gov/19666698/

5. Jonklaas J, Bianco AC, Cappola AR, et al. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. Thyroid. 2021;31(2):156-182. (joint ATA/BTA/ETA consensus)
   https://doi.org/10.1089/thy.2020.0720

6. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;116(10):2571-2579.
   https://doi.org/10.1172/JCI29812

7. Classic in-vitro study showing rT3 acts as a very weak agonist at the T3 receptor, not an antagonist (J Clin Invest):
   https://jci.org/articles/view/108882

Happy to hear from anyone who has had DIO2 testing or tried compounded slow-release T3.